Experimental immune therapy offers hope for Tough-to-Treat lymphoma

NCT ID NCT04531046

First seen Apr 04, 2026 · Last updated Apr 22, 2026 · Updated 2 times

Summary

This study is testing a personalized immune therapy called axi-cel for patients with aggressive B-cell lymphoma that has returned or not responded to initial treatment. The treatment involves collecting and genetically modifying the patient's own immune cells to attack cancer cells. Researchers want to see if this approach can achieve complete remission in patients who aren't eligible for stem cell transplant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA REFRACTORY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • APHP - Hôpital Henri Mondor

    Créteil, France

  • APHP - Hôpital Saint Louis

    Paris, 75475, France

  • CH Liège

    Liège, 4000, Belgium

  • CHU Brabois

    Vandœuvre-lès-Nancy, 54511, France

  • CHU Clermont Ferrand - Hôpital Estaing

    Clermont-Ferrand, France

  • CHU de Bordeaux - Hôpital Haut Lévêque

    Bordeaux, France

  • CHU de Dijon - Hôpital le Bocage

    Dijon, 21000, France

  • CHU de Nantes - Hôtel Dieu

    Nantes, 44093, France

  • CHU de Rennes - Hôpital de Pontchaillou

    Rennes, 35003, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, 69495, France

  • Hopital La Pitié Salpétriere

    Paris, France

  • Hôpital Claude Huriez

    Lille, 59037, France

  • Hôpital Saint Antoine

    Paris, France

  • Hôpital Saint Eloi

    Montpellier, 34295, France

  • IUCT Oncopole

    Toulouse, France

  • Institut de Cancérologie Gustave Roussy

    Villejuif, France

Conditions

Explore the condition pages connected to this study.